Home/Investors/New Enterprise Associates (NEA)

New Enterprise Associates (NEA)

Biotech Investor · 8 portfolio companies

Portfolio

8

Combined Value

$240M

Focus Areas

17

Top Stage

Phase 1

Investment Focus

Allergy & Immunology Inflammatory Diseases Fibrotic Diseases Immunology Autoimmune Diseases Neurodegenerative Diseases Ophthalmology Chronic Venous Insufficiency Vascular Disease Oncology Neurology Psychiatry Cardiology Radiology Precision Medicine

Portfolio Companies

Company	Stage	Valuation	Focus
Third Harmonic Bio	Phase 1b	$240M	Allergy & Immunology, Inflammatory Diseases
Iaso Bio	phase-1	—	Immunology, Autoimmune Diseases
AviadoBio	Phase 1	—	Neurodegenerative Diseases, Ophthalmology
Vesper Medical	Phase 3	—	Chronic Venous Insufficiency, Vascular Disease
Tempus	Commercial	—	Oncology, Neurology
Tagworks Pharmaceuticals	Phase 1	—	Oncology
Personal Genome Diagnostics	Commercial	—	Oncology
IDEAYA Biosciences, Inc.	Phase 2	—	Oncology, Precision Medicine

Frequent Co-Investors

Novartis Venture Fund2 shared Gilde Healthcare2 shared LifeArc Ventures1 shared OrbiMed1 shared 5AM Ventures1 shared Frazier Life Sciences1 shared Atlas Venture1 shared Johnson & Johnson Innovation – JJDC1 shared